Uncategorized Archives - BioMedWire (BMW)

ThursdayNov 06, 2025 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System

ECG data is necessary for the diagnosis of all cardiac arrhythmias in order to assess severity, implications and treatment options. HeartBeam is reporting that its 12-lead ECG synthesis software for arrhythmia assessment has been submitted to the U.S. Food and Drug Administration for 510(k) clearance. To enable smooth commercialization, the company is building the infrastructure needed to support widespread adoption. In the world of heart health, palpitations are common, with atrial fibrillation (“AF”) being one of the most typical sustained arrhythmias in adults (https://ibn.fm/8TSNY). HeartBeam (NASDAQ: BEAT) is on the verge of transforming how AF is detected and managed with…

TuesdayNov 04, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers

The financing initiatives underscore a disciplined approach to capital management at a critical stage for Soligenix. The company’s leadership has emphasized that this strengthened balance sheet allows Soligenix to focus on execution rather than financing. SNGX has outlined a timeline of catalysts extending through the end of 2026. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series of strategic capital initiatives, including a $7.5 million public offering (https://ibn.fm/QKXcv), the company now reports a cash…

MondayNov 03, 2025 12:45 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte(TM) (synthetic hypericin) and related therapies. These changes are timely given the complexities of CTCL and the evolving therapeutic landscape. The company’s decision to refresh its CTCL advisory team reflects a recognition that commercialization preparation in the CTCL space, evolving regulatory expectations and the need for robust trial designs demand expert insight. Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise…

MondayNov 03, 2025 12:00 pm

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”) Sapu-003 is an injectable formulation of Everolimus (Afinitor(R)), which aims to offer higher bioavailability and better efficacy than oral versions of the drug The trial is conducted alongside partners like the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003. The announcement occurred at the Australian Translational Breast Cancer Research…

TuesdayOct 28, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C. Soligenix’s ThermoVax(R) technology has broad applicability in Emerging Infectious Disease. Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in many outbreak regions (https://ibn.fm/MZWfk). Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has published a peer-reviewed summary of new…

WednesdayOct 22, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Breast Cancer Awareness Month by Addressing Gaps in Screening and Advancing the IzoView Breast CT Solution

Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true 3D imaging The IzoView breast CT scan technology is created for accurate, compression-free imaging for women who have dense breast tissue Increased screening demands and regulatory momentum underscore the opportunities for dedicated breast CT solutions IZOZF’s innovative approaches highlight the company’s mission to improve diagnosis, detection, and care for people globally Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device firm leading imaging-based solutions for better diagnosis, screening, and treatment of breast cancer patients, is bringing the challenges of current screening systems and the…

TuesdayOct 21, 2025 9:00 am

Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery

Sapu003 Phase 1 trial begins: Australian HREC approval validates Oncotelic’s proprietary 20nm nanoparticle technology for enhanced breast cancer drug delivery 20nm Deciparticle(TM) achieves full bioavailability: Intravenous delivery of Everolimus (Afinitor(R)) maximizes tumor targeting and efficacy compared to 10% absorption with oral formulations Rapid IND platform accelerates pipeline: Strategic partnership with Medicilon supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle(TM) drug candidates to reach clinical testing quickly Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle(TM) platform, beginning human trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor(R)). This scientific briefing explores…

ThursdayOct 16, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV ketamine formulation. The filing follows FDA approval of the company’s Suitability Petition to remove benzethonium chloride (“BZT”), a preservative linked to neurotoxicity. In parallel, NRx is advancing NRX-100, another preservative-free ketamine formulation under a New Drug Application (“NDA”) for suicidal ideation in depression, including bipolar depression. NRX-100 holds Fast Track Designation and may qualify for the FDA’s National Priority Voucher Program. The company also continues work on NRX-101, a Breakthrough Therapy for suicidal bipolar depression. CEO Dr. Jonathan Javitt recently discussed new pipeline developments and…

WednesdayOct 15, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advances AI-Powered Breast CT Innovation and Reinforces Its Commitment to Safer, Smarter Cancer Imaging

Izotropic recently published a piece that explores the way AI is redefining breast imaging and the way the innovative IzoView system was designed for the future The company’s 3D breast CT platform helps tackle one of the major concerns of cancer screening: radiation exposure in CT imaging With its trade-secret reconstruction algorithm, AI-native design, and fair price model, IzoView strategically places Izotropic to dominate the future of breast imaging technology These latest updates further highlight Izotropic’s mission: to redefine breast diagnostics using innovation that prioritizes safety, precision, and accessibility Izotropic (CSE: IZO) (OTCQB: IZOZF) is changing how breast cancer imaging is…

MondayOct 13, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

The closing of the public offering provides the company with critical financial flexibility as it continues to advance its pipeline of products. The $7.5 million raised through the public offering is particularly significant in the context of Soligenix’s ongoing clinical development programs. SNGX notes multiple potential value drivers over the next 18 months, including clinical milestones, regulatory interactions and data readouts across its pipeline. Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System

Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers

Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Breast Cancer Awareness Month by Addressing Gaps in Screening and Advancing the IzoView Breast CT Solution

Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advances AI-Powered Breast CT Innovation and Reinforces Its Commitment to Safer, Smarter Cancer Imaging

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search